A-195 Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing an Every-4-Week Dosing Schedule of Mogamulizumab in Patients with Cutaneous T-Cell Lymphoma.

Authors :: Scarisbrick, J.
Querfeld, C.
Akilov, O.
Bagot, M.
Córdoba, R.
Cowan, R.
García -Sancho, A.M.
Geskin, L.J.
Huen, A.O.
Jadwani, J.
Liu, Y.
Zhao, H.
Morris, S.
Ortiz-Romero, P.L.
Patel, A.
Pinter-Brown, L.C.
Pujol, R.M.
Quaglino, P.
Saba, N.S.
Vuppugalla, R.
Source :: European Journal of Cancer. 2024 Supplement 2, Vol. 211, pN.PAG-N.PAG. 1p.
Publication Year :: 2024

Subjects :: *THERAPEUTIC use of antineoplastic agents
*THERAPEUTIC use of monoclonal antibodies
*ANTINEOPLASTIC agents
*DRUG administration
*CONFERENCES & conventions
*CUTANEOUS T-cell lymphoma
*MONOCLONAL antibodies

Full Text Access

Tools